611
Views & Citations10
Likes & Shares
The Bipolar Androgen Therapy (BAT) is a novel strategy
of treatment for metastatic Prostate Cancer (mPC), currently under
investigation in many trials. The treatment schedule consists in alternating
standard Androgen Deprivation Therapy (ADT) with testosterone injections in
order to reach transitory supra-physiologic testosterone levels [1]. BAT aims to go
beyond the continuous androgen suppression, which is up-to-date essential
standard treatment for mPC in every phase of the disease, thus preventing
adaptation of mPC cells to a persistent low-androgen environment [2].
New generation
hormone therapies, such as enzalutamide and abiraterone, improved overall
survival in mPC patients who progressed to ADT [3-6] and more recent
trials suggest an even greater improvement of the outcomes when used in the
hormone-sensitive phase [7-10]. However, resistance
eventually occurs as mPC cells growth becomes partially independent of the
androgen receptor (AR) [11]. Therefore, new
strategies capable of delaying progression to metastatic castration resistant
prostate cancer (mCRPC) and at the same tFime restoring sensitivity to hormone
treatments are needed. In this context, BAT is attracting more and more
interest amng researches.
Keywords: Bipolar, Androgen, Therapy, Prostate, Cancer, Review
INTRODUCTION
Supraphysiological
stimulation of androgen receptor and its effect on mPC cells
AR plays a crucial
role in mPC growth and progression in every phase of the disease [1-11]. Thus, the blockage
of AR activity has represented the cornerstone of mPC treatment since the
seminal work of Huggins and colleagues [12]. However, it has
been proved that both AR pathway suppression and Supraphysiological Stimulation
of AR (SSA) result in growth inhibition, significant decrease in cells in S and
G2/M phases and apoptosis [13]. The mechanisms
behind this phenomenon have not been fully understood yet.
AR is directly involved in cell cycle progression in mPC cells, acting as a licensing factor for the initiation of DNA replication between G1 and S phases [14,15]. As a major component of the pre-replication complex, AR needs to be degraded in early G1 phase in order to allow a new pre-replication complex to identify DNA binding sites. SSA leads to overstabilization of the replication complex bound to the DNA, thus preventing DNA re-licencing [16]. SSA may also induce mPC cells senescence and apoptosis through various interaction between AR pathway, cyclin dependent kinase inhibitor and apoptosis regulator BAX protein [17–19]. Moreover, SSA could results in direct DNA damage. Haffner et al. proved that SSA causes dsDNA DNA-directed chemotherapy, such as etoposide, could improve anti-tumour activity of SSA. Finally, a transitory restoration of AR activity may inhibit the expression of AR splice variants and the activation of alternative (AR-independent) growth pathways [21-23].
Experiences with BAT in clinical trials
Testosterone-based treatments in mPC have been largely investigated over
the last 40 years [24]. However, only the
most recent trials should be considered for the purpose of evaluating the
efficacy of BAT, as only modern formulations of testosterone therapy are able
to effectively achieve SSA [25]. Importantly,
suspension of ADT alone is not enough to produce an acute raise in androgen
levels, allowing mPC cells to promptly adapt to the new environment.
Schweizer et al. [26]
enrolled 16 men with mCRPC to receive monthly testosterone intramuscular
injections (at the dose of 400 mg), associated with etoposide 100 mg/day on day
1 to 14. Radiographic response rate was 50% (8/16). Most notably, 100% of men
achieved PSA decline with subsequent second-line therapies, including 3 men
that received a therapy they have already progressed to, suggesting that BAT
may restore sensitivity to previous hormone-treatments [26]. In an open-label,
phase 2 clinical trials, 30 patients with MCPc were treated with BAT after
progression to enzalutamide. ORR was 50%. Among 29 patients who resumed
enzalutamide after progression to BAT, PSA response rate and progression-free
survival were 52% and 4.7 months, respectively [27]. In another trial,
33 treatment naïve patients with low metastatic burden prostate cancer or
biochemically recurrent disease were treated with 3 months cycles of BAT plus
continuous ADT, after six months of ADT alone. At the time point of 18 months,
59% of patients achieved PSA < 4 ng/mL, which was primary end point in this
trial [28]. The treatment was
safe and well-tolerated, with no severe adverse events detected. Lastly, 222
MCPc patients were enrolled in the TRASFORMER trial that randomized with a 1:1
ratio to testosterone cypionate/enanthate (400 mg of either agent injected
intramuscularly every 28 days) or enzalutamide (160 mg/day). Results are
available at clinicaltrials.gov. PFS was 5.62 months and 5.72 months, while
radiographic progression was 5.75 months and 8.72 months for BAT and
enzalutamide, respectively (NCT02286921).
FUTURE PERSPECTIVES
AND CONCLUSIONS
BAT showed promising
results in mPC patients, with a favourable safety profile and encouraging
activity signals. However, phase III randomized clinical trial are needed to
evaluate the real efficacy of BAT compared to standard therapies. At the
moment, clinical trials are on-going to investigate the efficacy of BAT alone
(NCT03522064), in association with olaparib (NCT03516812) and in association
with nivolumab (NCT03554317) in mCRPC patients. Secondary outcomes, such as
time to chemotherapy treatments and improvement in QoL, should be considered
carefully when evaluating BAT. Moreover, as PSA may not be a reliable marker of
response to BAT, future clinical trials should also consider different methods
of response evaluation, which may also include, alongside CT and bone scans,
liquid biopsy and direct evaluation of intracrine androgen biosynthesis
achieved through direct tumour tissue assessment.
1. Evans
CP (2018) Bipolar androgen therapy: An intriguing paradox. Lancet Oncol 19:
8-10.
2. Nemes
A, Tomuleasa C, Kacso G (2014) The androgen receptor remains a key player in
metastatic hormone-refractory prostate cancer: Implications for new treatments.
JBUON 19: 357-364.
3. Scher
HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. (2012) Increased survival
with Enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:
1187-1197.
4. Beer
TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, et al. (2014)
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med
371: 424-433.
5. de
Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. (2011) Abiraterone
and Increased Survival in Metastatic Prostate Cancer. N Engl J Med 364:
1995–2005.
6. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders
PFA, et al. (2015) Abiraterone acetate plus prednisone versus placebo plus
prednisone in chemotherapy-naive men with metastatic castration-resistant
prostate cancer (COU-AA-302): final overall survival analysis of a randomised,
double-blind, placebo-controlled phase 3 study. Lancet Oncol 16: 152-160.
7. Fizazi K, Tran N, Fein L, Matsubara N,
Rodriguez-Antolin A, et al. (2017) Abiraterone plus Prednisone in Metastatic,
Castration-Sensitive Prostate Cancer. N Engl J Med 377: 352-360.
8. Shore
ND, Chowdhury S, Villers A, Klotz L, Siemens RD, et al. (2016) Efficacy and
safety of enzalutamide versus bicalutamide for patients with metastatic
prostate cancer (TERRAIN): A randomised, double-blind, phase 2 study. Lancet
Oncol 17: 153-163.
9. James
ND, de Bono JS, Spears MR, Clarke NW, Mason MD, et al. (2017) Abiraterone for
prostate cancer not previously treated with hormone therapy. N Engl J Med 377:
338-351.
10. Penson
DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, et al. (2016) Enzalutamide
versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial.
J Clin Oncol 34: 2098-2106.
11. Buttigliero
C, Tucci M, Bertaglia V, Vignani F, Bironzo P, et al. (2015) Understanding and
overcoming the mechanisms of primary and acquired resistance to abiraterone and
enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 41:
884-892.
12. Huggins
C, Hodges CV (1941) Studies on prostatic cancer. I. The effect of castration,
of estrogen and of androgen injection on serum phosphatases in metastatic
carcinoma of the prostate. Cancer Res 1: 293-297.
13. de
Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F (1991) Characteristics of
the biphasic action of androgens and of the potent antiproliferative effects of
the new pure Antiestrogen EM-139 on Cell Cycle Kinetic Parameters in LNCaP
Human Prostatic Cancer Cells. Cancer Res 51: 5165-5170.
14. Litvinov
IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, et al. (2006)
Androgen receptor as a licensing factor for DNA replication in
androgen-sensitive prostate cancer cells. Proc Natl Acad Sci 103: 15085-15090.
15. Murthy
S, Wu M, Bai VU, Hou Z, Menon M, et al. (2013) Role of androgen receptor in
progression of LNCaP prostate cancer cells from G1 to S Phase. PLoS One 8:
e56692.
16. Nishitani
H, Lygerou Z (2002) Control of DNA replication licensing in a cell cycle. Genes
Cells 7: 523–534.
17. Mirochnik
Y, Veliceasa D, Williams L, Maxwell K, Yemelyanov A, et al. (2012) Androgen
receptor drives cellular senescence. PLoS One 7: e31052.
18. Denmeade
SR, Lin XS, Isaacs JT (2018) Role of programmed (apoptotic) cell death during
the progression and therapy for prostate cancer. Prostate 28: 251-265.
19. Lin
Y, Kokontis J, Tang F, Godfrey B, Liao S, et al. (2006) Androgen and its
receptor promote Bax-Mediated Apoptosis. Mol Cell Biol 26: 1908-1916.
20. Haffner
MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, et al. (2010) Androgen-induced
TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.
Nat Genet 42: 668.
21. Thelen
P, Heinrich E, Bremmer F, Trojan L, Strauss A (2013) Testosterone boosts for
treatment of castration resistant prostate cancer: An experimental
implementation of intermittent androgen deprivation. Prostate 73: 1699-1709.
Available online at: https://doi.org/10.1002/pros.22711
22. Kregel
S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, et al. (2013) Sox2 Is an androgen
receptor-repressed gene that promotes castration-resistant prostate cancer.
PLoS One 8: e53701.
23. Ruan
D, He J, Li C-F, Lee H-J, Liu J, et al. (2017) Skp2 deficiency restricts the
progression and stem cell features of castration-resistant prostate cancer by
destabilizing Twist. Oncogene 36: 4299.
24. Prout
GR, Brewer WR (2018) Response of men with advanced prostatic carcinoma to
exogenous administration of testosterone. Cancer 20: 1871-1878.
25. Szmulewitz
R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, et al. (2009) A Randomized
Phase 1 Study of Testosterone Replacement for Patients with Low-Risk
Castration-Resistant Prostate Cancer. Eur Urol 56: 97–104.
26. Schweizer
MT, Antonarakis ES, Wang H, Ajiboye AS, Cao H, et al. (2015) Effect of bipolar
androgen therapy for asymptomatic men with castration-resistant prostate
cancer. Sci Transl Med 7.
27. Teply
BA, Wang H, Luber B, Sullivan R, Rifkind I, et al. (2018) Bipolar androgen
therapy in men with metastatic castration-resistant prostate cancer after
progression on enzalutamide: An open-label, phase 2, multicohort study. Lancet
Oncol 19: 76-86.
28. Schweizer
MT, Wang H, Luber B, Nadal R, Spitz A, et al. (2016) Bipolar Androgen Therapy
for men with androgen ablation naïve prostate cancer: Results from the Phase II
BATMAN Study. Prostate 76: 1218-1226.
QUICK LINKS
- SUBMIT MANUSCRIPT
- RECOMMEND THE JOURNAL
-
SUBSCRIBE FOR ALERTS
RELATED JOURNALS
- Journal of Cancer Science and Treatment (ISSN:2641-7472)
- Journal of Nursing and Occupational Health (ISSN: 2640-0845)
- Advance Research on Alzheimers and Parkinsons Disease
- International Journal of Diabetes (ISSN: 2644-3031)
- Journal of Psychiatry and Psychology Research (ISSN:2640-6136)
- Journal of Rheumatology Research (ISSN:2641-6999)
- Journal of Infectious Diseases and Research (ISSN: 2688-6537)